Combined genome and transcriptome analysis of single disseminated cancer cells from bone marrow of prostate cancer patients reveals unexpected transcriptomes

Cancer Research

Volumn 74, Issue 24, 2014, Pages 7383-7394

  Gužvić, Miodrag ^a   Braun, Bernhard ^a,b   Ganzer, Roman ^a   Burger, Maximilian ^a   Nerlich, Michael ^c   Winkler, Sebastian ^a   Werner Klein, Melanie ^a   Czyz, Zbigniew T ^d   Polzer, Bernhard ^d   Klein, Christoph A ^a,d  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Barmherzige Brüder Hospital   (Germany)

^c UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^d Project Group Personalized Tumour Therapy Fraunhofer Institute of Experimental Medicine and Toxicology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CYTOKERATIN 14; CYTOKERATIN 18; CYTOKERATIN 19; CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 6A; CYTOKERATIN 8; EPITHELIAL CELL ADHESION MOLECULE; GLYCOPHORIN A; HEMOGLOBIN A2; MELANOMA ANTIGEN 2; MELANOMA ANTIGEN 4; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTOME; UNCLASSIFIED DRUG; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MESSENGER RNA; TUMOR ANTIGEN; TUMOR PROTEIN;

ADULT; ARTICLE; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW METASTASIS; CANCER CELL; CANCER PATIENT; CANCER STAGING; CD19 GENE; CD33 GENE; CD34 GENE; CELL ISOLATION; CELL SELECTION; CONTROLLED STUDY; DISSEMINATED CANCER CELL; EPCAM GENE; GENE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENOME ANALYSIS; GYPC GENE; HBA2 GENE; HUMAN; HUMAN CELL; KLK3 GENE; KRT14 GENE; KRT19 GENE; KRT5 GENE; KRT6A GENE; KRT8 GENE; MAGEA2 GENE; MAGEA4 GENE; MAJOR CLINICAL STUDY; MALE; MICROMANIPULATION; PROSTATE CANCER; PTPRC GENE; RNA ANALYSIS; SCL4A1 GENE; SINGLE CELL ANALYSIS; AGED; BIOSYNTHESIS; BONE TUMOR; GENETICS; HUMAN GENOME; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; SECONDARY;

ADULT; AGED; ANTIGENS, NEOPLASM; BONE MARROW; BONE NEOPLASMS; CELL ADHESION MOLECULES; GENOME, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RNA, MESSENGER; TRANSCRIPTOME;

EID: 84918593578     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-0934     Document Type: Article

References (47)

1. Brabletz T, Lyden D, Steeg PS, Werb Z. Roadblocks to translational advances on metastasis research. Nat Med 2013;19:1104-9.
2. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, et al. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004;10:6897-904.
3. Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005;353:793-802.
4. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008;13:441-53.
5. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, et al. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009;27:1549-56.
6. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, et al. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002;360:683-9.
7. Hartmann CH, Klein CA. Gene expression profiling of single cells on large-scale oligonucleotide arrays. Nucleic Acids Res 2006;34:e143.
8. Morgan TM, Lange PH, Porter MP, Lin DW, Ellis WJ, Gallaher IS, et al. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence. Clin Cancer Res 2009;15:677-83.
9. Klein CA. The systemic progression of human cancer: a focus on the individual disseminated cancer cell-the unit of selection. Adv Cancer Res 2003;89:35-67.
10. Klein CA, Seidl S, Petat-Dutter K, Offner S, Geigl JB, Schmidt-Kittler O, et al. Combined transcriptome and genome analysis of single micrometastatic cells. Nat Biotechnol 2002;20:387-92.
11. Choesmel V, Anract P, Hoifodt H, Thiery JP, Blin N. A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases. Cancer 2004;101:693-703.
12. Fehm T, Braun S, Muller V, Janni W, Gebauer G, Marth C, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer 2006;107:885-92.
13. Klein CA, Schmidt-Kittler O, Schardt JA, Pantel K, Speicher MR, Riethmuller G. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells. Proc Natl Acad Sci U S A 1999;96:4494-9.
14. Czyz ZT, Hoffmann M, Schlimok G, Polzer B, Klein CA. Reliable Single Cell Array CGH for Clinical Samples. PLoS ONE 2014;9:e85907.
15. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 1998;95:14863-8.
16. Schardt JA, Meyer M, Hartmann CH, Schubert F, Schmidt-Kittler O, Fuhrmann C, et al. Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer. Cancer Cell 2005;8:227-39.
17. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871-90.
18. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, et al. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007;13:5001-9.
19. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA Jr, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005;27:49-57.
20. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, et al. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol 2012;9:016002.
21. Munz M, Fellinger K, Hofmann T, Schmitt B, Gires O. Glycosylation is crucial for stability of tumour and cancer stem cell antigen EpCAM. Front Biosci 2008;13:5195-201.
22. Yang Y, Hao J, Liu X, Dalkin B, Nagle RB. Differential expression of cytokeratin mRNA and protein in normal prostate, prostatic intraepithelial neoplasia, and invasive carcinoma. Am J Pathol 1997;150:693-704.
23. van Leenders GJ, Schalken JA. Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 2003;46:S3-10.
24. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
25. Schmelz M, Moll R, Hesse U, Prasad AR, Gandolfi JA, Hasan SR, et al. Identification of a stem cell candidate in the normal human prostate gland. Eur J Cell Biol 2005;84:341-54.
26. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 1994;12:337-65.
27. Mecklenburg I, Weckermann D, Zippelius A, Schoberth A, Petersen S, Prang N, et al. A multimarker real-time RT-PCR for MAGE-A gene expression allows sensitive detection and quantification of the minimal systemic tumor load in patients with localized cancer. J Immunol Methods 2007;323:180-93.
28. Mueller P, Carroll P, Bowers E, Moore D II, Cher M, Presti J, et al. Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998;83:538-46.
29. Riesenberg R, Oberneder R, Kriegmair M, Epp M, Bitzer U, Hofstetter A, et al. Immunocytochemical double staining of cytokeratin and prostate specific antigen in individual prostatic tumour cells. Histochemistry 1993;99:61-6.
30. Ellis WJ, Pfitzenmaier J, Colli J, Arfman E, Lange PH, Vessella RL. Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology 2003;61:277-81.
31. Pfitzenmaier J, Ellis WJ, Hawley S, Arfman EW, Klein JR, Lange PH, et al. The detection and isolation of viable prostate-specific antigen positive epithelial cells by enrichment: a comparison to standard prostate-specific antigen reverse transcriptase polymerase chain reaction and its clinical relevance in prostate cancer. Urol Oncol 2007;25:214-20.
32. Buhring HJ, Muller T, Herbst R, Cole S, Rappold I, Schuller W, et al. The adhesion molecule E-cadherin and a surface antigen recognized by the antibody 9C4 are selectively expressed on erythroid cells of defined maturational stages. Leukemia 1996;10:106-16.
33. Lammers R, Giesert C, Grunebach F, Marxer A, Vogel W, Buhring HJ. Monoclonal antibody 9C4 recognizes epithelial cellular adhesion molecule, a cell surface antigen expressed in early steps of erythropoiesis. Exp Hematol 2002;30:537-45.
34. Israels LG, Israels ID. Erythropoiesis: an overview. In:Molineux G, Foote MA, Elliott SG, editors. Erythropoietins and erythropoiesis. Basel, Switzerland: Birkhäuser Verlag; 2003. p. 3-14.
35. Fukuda M, Fukuda MN, Papayannopoulou T, Hakomori S. Membrane differentiation in human erythroid cells: unique profiles of cell surface glycoproteins expressed in erythroblasts in vitro from three ontogenic stages. Proc Natl Acad Sci U S A 1980;77:3474-8.
36. Villeval JL, Le Van Kim C, Bettaieb A, Debili N, Colin Y, el Maliki B, et al. Early expression of glycophorin C during normal and leukemic human erythroid differentiation. Cancer Res 1989;49:2626-32.
37. Attard G, Swennenhuis JF, Olmos D, Reid AH, Vickers E, A'Hern R, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
38. Yu M, Ting DT, Stott SL, Wittner BS, Ozsolak F, Paul S, et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 2012;487:510-3.
39. Ozkumur E, Shah AM, Ciciliano JC, Emmink BL, Miyamoto DT, Brachtel E, et al. Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cells. Sci Transl Med 2013;5:179ra47.
40. Capulli M, Angelucci A, Driouch K, Garcia T, Clement-Lacroix P, Martella F, et al. Increased expression of a set of genes enriched in oxygen binding function discloses a predisposition of breast cancer bone metastases to generate metastasis spread in multiple organs. J Bone Miner Res 2012;27:2387-98.
41. Gorr TA, Wichmann D, Pilarsky C, Theurillat JP, Fabrizius A, Laufs T, et al. Old proteins - new locations: myoglobin, hemoglobin, neuroglobin and cytoglobin in solid tumours and cancer cells. Acta Physiol 2011;202:563-81.
42. Zhang S, Mercado-Uribe I, Liu J. Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett 2013;333:205-12.
43. Shiozawa Y, Pedersen EA, Havens AM, Jung Y, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest 2011;121:1298-312.
44. Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal 2014;7:ra63.
45. Emara M, Turner AR, Allalunis-Turner J. Hypoxia differentially upregulates the expression of embryonic, fetal and adult hemoglobin in human glioblastoma cells. Int J Oncol 2014;44:950-8.
46. Liu W, Baker SS, Baker RD, Nowak NJ, Zhu L. Upregulation of hemoglobin expression by oxidative stress in hepatocytes and its implication in nonalcoholic steatohepatitis. PLoS ONE 2011;6:e24363.
47. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, Mason MD, et al. Guidelines on prostate cancer: European Association of Urology; Arnhem, the Netherlands, 2012.